Kailera Therapeutics isn’t the only company developing an obesity drug that hits multiple targets for weight loss, but the clinical-stage biotech believes its lead drug candidate can beat other medicines in helping patients shed body weight. With that in-licensed drug now in pivotal testing, Kailera is starting to build its case for investors in the public markets.
Waltham, Massachusetts-based Kailera filed its IPO paperwork after Friday’s market close. As is typical of such initial filings, there are no financial details yet about how many shares the company plans to offer and how much it aims to raise. Kailera has applied for a Nasdaq listing under the stock symbol “KLRA.”
Lead Kailera drug candidate ribupatide, formerly known as KAI-9531, is an injectable peptide engineered to activate GLP-1 and GIP receptors in the gastrointestinal tract. Hitting both receptors with a single drug has validation from tirzepatide, the blockbuster injectable Eli Lilly peptide drug marketed as Zepbound. But in its IPO filing, Kailera said there’s still an unmet need for patients with high body mass indexes (BMI). The company notes that in Zepbound’s Phase 3 test, most patients had a baseline BMI of 35 or greater and were still living with obesity at the end of the study’s treatment period.
While ribupatide hits the same targets as Zepbound, it’s engineered to offer a better clinical profile. Specifically, the peptide is designed to have greater binding affinity to its target receptors and a longer half-life that improves the drug’s exposure in the body through the full weekly dosing period.
“We believe this profile could result in the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better,” Kailera said in the filing.
The company goes on to say that it has not evaluated ribupatide head to head against other obesity drugs, approved or in clinical development. The clinical program consists of three Phase 3 studies, two enrolling patients who do not have diabetes and one enrolling participants who do. All three are comparing the study drug to a placebo. Last month, an oral version of the Kailera drug posted positive results from a Phase 2 test in China; a global mid-stage study is expected to begin later this year.
There are other companies developing obesity drugs that target both GLP-1 and GIP. Last week, China-based BrightGene reported positive Phase 1 results for BGM0504, an oral drug designed to hit those targets. The study enrolled participants in both China and the U.S. Roche has encouraging preliminary Phase 2 results for its once-weekly injectable GLP-1/GIP receptor agonist, CT-388. The pharma company said it plans to further evaluate this drug in combination with petrelintide, an amylin receptor-targeting peptide drug in development under a partnership with Zealand Pharma. Viking Therapeutics is in the mix with dual GLP-1 and GIP receptor-targeting drug called VK2735. The injectable formulation is currently in Phase 3 testing. An oral version of the Viking drug is expected to start its Phase 3 test in the third quarter of this year.
Kailera formed in 2024, built around four metabolic drug candidates licensed from China-based Jiangsu Hengrui Pharmaceuticals. The IPO filing states Kailera paid $100 million upfront, plus a $10 million technology transfer fee. Hengrui also gained an equity stake in the biotech company. The filing shows Hengrui owns 13.6% of Kailera prior to the IPO. The biotech’s largest shareholder is Bain Capital Life Sciences Fund, which currently holds a 24.8% stake. Since its inception, Kailera said it has raised about $900 million from Bain and other life science investors, including a $600 million Series B financing announced last October.
As of the end of 2025, Kailera’s cash position was $652.7 million. In the filing, the company said it will apply that cash and the IPO proceeds toward continued development of ribupatide, both the once-weekly injectable version and a once-daily oral formulation. Kailera also plans to use the capital to continue development of its oral GLP-1 drug, KAI-7535.
Kailera is dipping its toe in an IPO market that began recovering in January and February with a series of successfully completed offerings from biotech companies. The momentum slowed in March. Tariff turmoil and war in the Middle East are among the factors contributing to market volatility that continues to dampen IPO activity, Renaissance Capital said in its first quarter 2026 U.S. IPO market review.
Across all sectors, Renaissance counted a total of 34 companies that went public in the quarter, raising $9.9 billion. While that total is lower compared to the same period in prior years, the IPOs that were completed included some sizable offerings. Of the 34 first quarter IPOs, 22 raised $100 million or more. Investors still showed appetite for select growth stories, particularly in biotech as well as “AI-resistant” real economy businesses, such as companies in power infrastructure, according to the report. Moreover, there’s still a sizeable backlog of companies waiting to go public.
“While volatility dashed hopes for an early start to the IPO rebound, decent returns from the quarter’s deals signal that the IPO market can still find solid ground when markets stabilize, and many potential issuers have indicated that they expect to stick to their 2026 listing plans, including highly-anticipated names like SpaceX and OpenAI,” Renaissance said.
Photo: Jason Dean, Getty Images
